
Aptorum Group Limited APM
$ 0.96
-5.75%
Annual report 2024
added 03-21-2026
Aptorum Group Limited Total Assets 2011-2026 | APM
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Aptorum Group Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.1 M | 20.6 M | 20.9 M | 21.9 M | 44.2 M | 24 M | 45.1 M | 31.6 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.1 M | 16.1 M | 28 M |
Quarterly Total Assets Aptorum Group Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 21.9 M | - | 31.7 M | - | 44.2 M | - | 23.3 M | - | 24 M | - | - | - | 45.1 M | - | - | - | 31.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.1 M | 21.9 M | 31.7 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
12.9 T | $ 18.06 | - | $ 28.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 19.44 | -0.46 % | $ 909 M | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | ||
|
Protara Therapeutics
TARA
|
209 M | $ 5.03 | -3.08 % | $ 215 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Tarsus Pharmaceuticals
TARS
|
562 M | $ 67.0 | -0.3 % | $ 2.8 B | ||
|
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
Theravance Biopharma
TBPH
|
486 M | $ 14.9 | -1.91 % | $ 750 M | ||
|
Avid Bioservices
CDMO
|
337 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.2 | -6.97 % | $ 306 M | ||
|
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B | ||
|
Bio-Techne Corporation
TECH
|
2.56 B | $ 51.31 | -2.65 % | $ 8.08 B | ||
|
Tenax Therapeutics
TENX
|
104 M | $ 14.64 | -2.2 % | $ 574 M | ||
|
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
126 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
27.7 M | $ 1.07 | -2.29 % | $ 21.9 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
40.7 B | $ 28.76 | -3.43 % | $ 32.9 B | ||
|
Enochian Biosciences
ENOB
|
8.23 M | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | ||
|
Equillium
EQ
|
31.9 M | $ 2.03 | -1.46 % | $ 116 M | ||
|
Eton Pharmaceuticals
ETON
|
92.1 M | $ 23.81 | 1.51 % | $ 641 M | ||
|
Bellerophon Therapeutics
BLPH
|
7.94 M | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
2.27 B | $ 46.38 | -2.45 % | $ 4.17 B |